Science

Targeting the cell cycle for cancer therapy: From the discovery of CDK9 to precision medicine and beyond

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 15/10/2026, 20:55:24 UTC.

Briefings

A recent paper reviews over 30 years of cyclin-dependent kinase (CDK) research, tracing its evolution from initial discovery to modern precision medicine approaches. The study outlines the next generation of CDK-targeted therapies, highlighting the long-standing connection between molecular machinery controlling cell division and cancer. The research provides a comprehensive historical context for current therapeutic strategies.

Key points

• The study traces the evolution of cyclin-dependent kinase research over more than 30 years.
• It outlines the next generation of CDK-targeted therapies in precision medicine.

Context

This research builds on the established connection between molecular machinery controlling cell division and cancer, providing a historical overview for current therapeutic strategies.

Limitations

The evidence is limited to a single paper's review of over 30 years of CDK research. Specific dates, authors, or detailed clinical trial data are not provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/10/2026, 00:37:59 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifj2vq26ydkh6mk6mrycbykpuikhg7k23us3czlx4fxttkeluqday